Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland
Celebrating its strategic milestone opening in an emerging biotech hub, Amador welcomed many distinguished guests to its new facilities on the I-270 corridor.
Sponsored by ECBuild / EwingCole
Nov 1, 2022 – Germantown, Md.: Amador Bioscience, a global translational and clinical research CRO, is pleased to announce the grand opening of its GxP lab in Germantown, Maryland, on October 28, 2022. The 10,000+ square foot bioanalytical laboratory joins the company’s other facilities, which opened earlier this year in Belgium, China, and Ann Arbor, Michigan.
Friday’s grand opening celebration and ribbon cutting included several distinguished guests from leading biopharmaceutical companies, the Belgium embassy, FDA, and the local Maryland community, including:
- Admiral Estella Jones, DVM, Deputy Director, Office of Counterterrorism and Emerging Threats, Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration
- John Baekelmans, Belgium Flanders Investment & Trade Science and Technology Counselor
- Bart Boschmans, Belgium Flanders Investment & Trade Economic Counselor
- Marc Elrich, Montgomery County Executive
- Dr. Lorin Roskos, Senior Vice President, Exelixis
- Dr. Koustubh Ranade, Vice President & Head of Translational Medicine, Immunocore
- Dr. Binodh DeSilva, Vice President, Bristol Myers Squibb; President of American Association of Pharmaceutical Scientists (2017)
- Dr. Honghui Zhou, Vice President, Head of Clinical Pharmacology and Toxicology, Kira Pharmaceuticals
Founded in 2018, Amador’s vision is to be the leading global partner for biotherapeutics clinical development success for companies developing novel biotherapeutics. Over the last four years, the company has laid a foundation for clinical-stage development in several biotech hubs, supporting the industry worldwide from pre-clinical development to successful market approval.
“Our company’s values of integrity, excellence, collaboration, and courage are vital components in directing how we are achieving this mission here in Maryland and around the world,” Xiaomin Chen, MBA, Chief Operations Officer at Amador shared at the opening celebration. “We are confident that our world-class bioanalysis and biomarker, and clinical development capabilities, and the strong scientific skill sets and experience of our employees — now and in the future — will propel our local biopharmaceutical companies toward their development goals.”
The grand opening of Amador’s lab at Observation Labs on the growing and thriving I-270 corridor highlights a major milestone in the company’s journey. Under the guidance of Dr. Meina Liang, Chief Technology Officer and President of Bioanalysis and Biomarkers at Amador Bioscience, and Rafiq Islam, Vice President of Bioanalysis and Biomarkers in Maryland, the new lab will employ over 100 scientists by the end of 2023.
The Maryland facility — together with the company’s other global sites and teams specialized in bioanalysis and biomarkers, clinical pharmacology, biometrics, regulatory affairs, and clinical research — provides Amador’s clients with an integrated solution for drug development.
Specifically, the facility in Maryland offers advanced bioanalytical technologies such as flow cytometry, digital PCR, qPCR, and LCMS, as well as ligand binding assay and cell-based assay capabilities. These state-of-the-art technologies allow Amador’s expert scientific team to devise bioanalytical strategies that minimize risk and bring investigational drugs to market safely and efficiently.
With an additional 10,400 square foot expansion planned for early 2023, Amador will quickly make space for 75 more scientists to join its organization in Germantown, Maryland. The next major step in the company’s expansion includes opening another GxP bioanalytical lab in Pleasanton, California, by December 2022.
For further information please contact our team or visit amadorbioscience.com.
About Amador Bioscience
Amador Bioscience is a global translational and clinical CRO, providing global-standard (GLP/GCP) laboratory, clinical research, strategy consulting, and regulatory filing services to leading pharmaceutical companies in both China and the U.S. The laboratory services focus on bioanalysis, biomarkers and immunogenicity assessment. The clinical research unit specializes in innovative clinical development strategy, protocol design, study initiation and monitoring of clinical studies in the US and China. In addition to the R&D strategy and regulatory pathway, the consulting services perform global-standard data analysis and generate submission-ready study reports.
Discover the latest projects making an impact in the region and the companies building them. Click below…
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
